Atrial Flutter Clinical Trial
Official title:
Randomised Prospective Trial Comparing Contact Force and Non-contact Force Guided Catheter Ablation for Cavotricuspid Isthmus Dependent Atrial Flutter
Verified date | May 2020 |
Source | Victoria Cardiac Arrhythmia Trials |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Radiofrequency ablation (RFA) is a standard treatment option for cavotricuspid isthmus (CTI) dependent atrial flutter. We plan to perform a randomized prospective trial comparing the efficacy of contact force (CF) guided CTI ablation against catheter ablation with the operator blinded to contact force parameters.
Status | Enrolling by invitation |
Enrollment | 100 |
Est. completion date | December 2020 |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patients (over the age of 18) with 12 lead ECG documented paroxysmal or persistent CTI dependent atrial flutter planned to undergo CTI ablation. - Able and willing to give informed consent. Exclusion Criteria: - Previous CTI ablation - Previous non-CTI dependent atrial flutter (ie.patients with previous history of pulmonary vein isolation or left atrial ablation, congenital heart disease, surgical ablation) |
Country | Name | City | State |
---|---|---|---|
Canada | Victoria Cardiac Arrhythmia Trials | Victoria | British Columbia |
Lead Sponsor | Collaborator |
---|---|
Victoria Cardiac Arrhythmia Trials |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of RFA | Total RFA time required to achieve bidirectional block | Determined during RFA procedure | |
Secondary | Recurrence of atrial flutter | Documented recurrence of atrial flutter | Assessed at 12 weeks and 12 months post CTI RFA procedure | |
Secondary | Average total CF achieved | Average total CF per ablation per segment (third) of the CTI. | Determined during RFA procedure | |
Secondary | Average axial CF achieved | Average axial CF per ablation per segment (third) of the CTI. | Determined during RFA procedure | |
Secondary | Average FTI achieved | Average FTI per ablation per segment (third) of the CTI. | Determined during RFA procedure | |
Secondary | Average lateral CF achieved | Average lateral CF per ablation per segment (third) of the CTI. | Determined during RFA procedure | |
Secondary | Average lesion size index (LSI) achieved | Average lesion size index (LSI) per ablation per segment (third) of the CTI. | Determined during RFA procedure | |
Secondary | Procedural complication rate | Incidence of procedural complications: stroke, cardiac perforation, steam pops, access site bleeding. | Determined during RFA procedure and at 12 weeks post RFA procedure | |
Secondary | Average total CF of segment of acute and delayed reconnection | Average total CF per ablation in segment (third) of acute or delayed reconnection. | Determined during index and repeat RFA procedure | |
Secondary | Average lateral CF of segment of acute and delayed reconnection | Average lateral CF per ablation in segment (third) of acute or delayed reconnection. | Determined during index and repeat RFA procedure | |
Secondary | Average axial CF of segment of acute and delayed reconnection | Average axial CF per ablation in segment (third) of acute or delayed reconnection. | Determined during index and repeat RFA procedure | |
Secondary | Average FTI of segment of acute and delayed reconnection | Average FTI per ablation in segment (third) of acute or delayed reconnection. | Determined during index and repeat RFA procedure | |
Secondary | Average lesion size index (LSI) of segment of acute and delayed reconnection | Average lesion size index (LSI) per ablation in segment (third) of acute or delayed reconnection. | Determined during index and repeat RFA procedure | |
Secondary | Procedural efficacy of RFA | Total procedural time required to achieve bidirectional block | Determined during RFA procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Terminated |
NCT02317029 -
Comparison of Oxygen Interventions and Defibrillator Efficiency
|
N/A | |
Recruiting |
NCT01563848 -
Cryoablation in Patients With Atrial Flutter
|
Phase 2 | |
Completed |
NCT01229254 -
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
|
Phase 2 | |
Completed |
NCT00839657 -
Clarification of Optimal Anticoagulation Through Genetics
|
Phase 3 | |
Completed |
NCT02065388 -
Pharmacogenetic Dosing of Warfarin
|
Phase 3 | |
Completed |
NCT00232232 -
Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
|
Phase 4 | |
Completed |
NCT04884100 -
enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening
|
N/A | |
Completed |
NCT05468281 -
RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
|
||
Completed |
NCT03627143 -
Decreasing Hospital Admissions From the ED for AAFF
|
N/A | |
Completed |
NCT02917538 -
A Randomized Trial of Contact Force in Atrial Flutter Ablation
|
N/A | |
Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
Recruiting |
NCT05755074 -
Ablation of Typical Right Atrial Flutter
|
N/A | |
Recruiting |
NCT05883631 -
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
|
N/A | |
Recruiting |
NCT03272620 -
Atrial Fibrillation at the Viennese University Emergency Department
|
N/A | |
Completed |
NCT02810938 -
MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
|
||
Recruiting |
NCT02591875 -
Atrial Flutter Ablation in a Real World Population
|
N/A | |
Completed |
NCT01914497 -
Dipole Density Mapping of Typical Atrial Flutter
|
N/A | |
Completed |
NCT02268799 -
High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter
|
N/A | |
Active, not recruiting |
NCT01976507 -
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
|
Phase 4 |